Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 Co-receptor

Journal of Infectious Diseases

Volumn 202, Issue 5, 2010, Pages 739-744

  Veazey, Ronald S ^a   Ketas, Thomas J ^b   Dufour, Jason ^a   Moroney Rasmussen, Terri ^a   Green, Linda C ^a   Klasse, P J ^b   Moore, John P ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIREMIA; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; CYCLOHEXANES; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; RECEPTORS, CCR5; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; TRIAZOLES; VAGINAL DISEASES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 77955673220     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655661     Document Type: Article

References (28)

1. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6:20-28.
2. Cohen MS, Kaleebu P, Coates T. Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc 2008; 11:4.
3. Lederman MM, Jump R, Pilch-Cooper HA, Root M, Sieg SF. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology 2008; 5:116.
4. Klasse PJ, Shattock RJ, Moore JP. Anti-retroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-471.
5. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 2006; 4:312-317.
6. MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47:236-241.
7. International Partnership for Microbicides. Developing HIV-prevention options for women worldwide. http://www.ipmglobal.org/news-room/english/press- releases/2008/20080130-pfizer.htm. Accessed 28 June 2010.
8. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485-487.
9. Veazey RS, Klasse PJ, Schader S, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102.
10. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005; 11:1293-1294.
11. Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides? Science 2008; 321:532-534.
12. Ketas TJ, Schader SM, Zurita J, et al. Entry inhibitor-basedmicrobicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 2007; 364:431-440.
13. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-1089.
14. Veazey RS, Ketas TJ, Klasse PJ, et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV- 1 fusion inhibitor T-1249. Proc Natl Acad Sci USA 2008; 105: 10531-10536.
15. Joag SV, Li Z, Foresman L, et al. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques. AIDS Res Hum Retroviruses 1997; 13(8): 635-645.
16. Harouse JM, Gettie A., Eshetu T, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 2001; 75(4):1990-1995.
17. Hladik, F, Sakchalathorn P., Ballweber B, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257-270.
18. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005; 308:1582-1583.
19. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-1134.
20. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009; 83:3556-33567.
21. Hawkins C, Murphy RL. Management of antiretroviral failure and resistance in developing countries. Curr Opin HIV AIDS 2009; 4:538-544.
22. Wolinsky SM, Veazey RS, Kunstman KJ, et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004; 328:19-29.
23. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.
24. Dudley DM, Wentzel JL, Lalonde MS, Veazey RS, Arts EJ. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol 2009; 83:5067-5076.
25. Witter FR, Barditch-Crovo P, Rocco L, Trapnell CB. Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol- 9 containing intravaginal contraceptives. Int J Gynaecol Obstet 1999; 65:165-170.
26. Malcolm K, Woolfson D, Toner C, Lowry D. Vaginal microbicides for the prevention of HIV transmission. Biotechnol Genet Eng Rev 2004; 21:81-121.
27. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J 2009; 11:78-87.
28. Romano J, Variano B, Coplan P, et al. Safety and availability of Dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25:483-488.